One dose. That's what the cancer patients in this trial received. A single, carefully supervised session with psilocybin — the compound in psychedelic mushrooms — and then they went home to live the rest of their lives. Five years later, most of them still describe it as one of the most meaningful experiences they've ever had.

That's a striking claim, and it deserves to be examined carefully rather than just admired. The relationship between psilocybin, addiction, depression, and the kind of existential dread that comes with a cancer diagnosis is one of the more compelling threads in current psychedelic research. It also sits at the heart of why so many people are quietly looking into psychedelic retreats — not for recreation, but because they're trying to find a way out of something that talk therapy and medication haven't touched.

So let's walk through what the New York University team actually found, what it means, and what it doesn't.

What the NYU psilocybin cancer study actually tested

The original trial enrolled 29 cancer patients dealing with anxiety and depression linked to their diagnosis. Roughly 40% of people with cancer experience this kind of psychological distress — the constant low hum of fear about recurrence, about pain, about death, about the people they'll leave behind. Standard antidepressants help some patients. Many others find them flat, dulling, or simply ineffective for this particular flavor of suffering.

Each participant received a single dose of psilocybin in a supervised therapeutic setting, paired with psychotherapy before and after. The setting matters. This wasn't a pill handed over with a glass of water. It was hours spent lying on a couch, eye shades on, music playing, with two trained guides nearby. The session itself typically runs around six hours.

The short-term results — reported in 2016 — were already remarkable. Patients showed dramatic drops in measures of anxiety and depression within weeks. What nobody knew was whether those effects would hold.

The five-year follow-up: durability of a single session

In the long-term follow-up, researchers tracked down the surviving participants and asked them, in detail, how they were doing. Around 80% still reported clinically significant reductions in anxiety and depression. Most rated the psilocybin session as among the top five most meaningful experiences of their entire lives — comparable, for many, to the birth of a child or the death of a parent. Roughly 96% called it one of the most spiritually significant experiences they'd ever had.

Prior to this work, the longest follow-up in any modern psychedelic trial had been twelve months. Five years is a different order of evidence. It suggests something more than a temporary mood lift. It suggests that whatever shifted in these patients had become part of how they live.

One participant put it plainly: even after being diagnosed with a second, unrelated cancer years later, the dread that used to swallow her whole simply wasn't there anymore. She got the tests. She had the operations. She kept moving.

What participants said had actually changed

The qualitative reports are where the study gets genuinely interesting. The numbers tell you something measurable shifted; the words tell you what the shift felt like from the inside.

• One participant who had spent decades avoiding social situations said the experience of overwhelming love during the session gave her enough confidence to throw a birthday party. People came. She was stunned.
• Another said they were creating again — writing, performing, taking risks they hadn't taken since their twenties.
• A third described the change with a single sentence: something in me softened, and I realized everyone is just trying, mostly, to do the best they can.

That last one is the kind of insight people spend decades in therapy trying to reach. None of this is mystical accounting. These are normal people describing what it's like to be less afraid.

Why might one session do this? The current theories

Researchers genuinely don't know yet, and the honest ones say so. But a few hypotheses keep showing up in the literature.

One is that psilocybin temporarily quiets the default mode network — the part of the brain associated with the running narrative of self, the inner monologue, the rumination loop. When that network goes offline, the rigid sense of "I am this person with this disease and this future" loosens. Patients describe stepping outside themselves and seeing their lives from a different angle. Sometimes what they see changes them.

Another idea is that psychedelics increase neural flexibility — they make the brain more receptive to new ideas, new emotional patterns, new ways of organizing memory. Robin Carhart-Harris, one of the more prominent researchers in the field, has described it as a kind of lubrication: cogs that had been stuck for years suddenly turning freely. Whether that lubrication lasts depends on what you do with it afterward, which is why integration — the unsexy work of making sense of the experience in the weeks and months that follow — gets so much attention in serious psychedelic therapy.

How this fits into the broader picture of psychedelic healing

The NYU work doesn't sit alone. Johns Hopkins has run parallel studies with similar results. Trials on psilocybin for treatment-resistant depression, on MDMA for PTSD, on ibogaine for opioid dependence, on ayahuasca for addiction and trauma — they keep producing the same shape of result. Durable effects from a small number of sessions, in carefully supported settings, when standard treatments haven't worked.

This is also why master plants and synthesized psychedelics keep showing up in the same conversation. The traditions around ayahuasca, San Pedro, and psilocybin mushrooms have understood for centuries that these substances can crack open something fixed — a fear, a grief, a way of seeing yourself — and that the cracking only heals well if there's care around it. Modern clinical trials are, in a sense, rediscovering what curanderos already knew, just with statistical significance attached.

The legal landscape is shifting too. Oregon and Colorado now have regulated psilocybin therapy programs. Several U.S. cities have decriminalized personal use. Australia legalized psilocybin for treatment-resistant depression under specialist prescription. None of this makes the substances casual — they remain serious — but it does mean access is broadening for the first time in half a century.

What this means for someone considering a retreat

If you've been reading research like the NYU study and quietly wondering whether a psilocybin retreat — or an ayahuasca ceremony, or another plant-medicine experience — might help you with something stuck in your own life, a few honest notes.

1. Setting matters enormously. The trial results came from supervised sessions with trained therapists and integration support. A weekend in a beautiful jungle isn't automatically equivalent. Vet facilitators carefully. Ask about medical screening, about what happens if a session goes hard, about what aftercare looks like.
2. Screen yourself honestly. Psilocybin and ayahuasca interact badly with certain medications (SSRIs, MAOIs, lithium) and aren't appropriate for people with personal or family history of psychosis. A reputable retreat will ask. If they don't, that's a red flag.
3. Don't expect one session to do all the work. The patients in the study had weeks of preparation and follow-up therapy. The medicine opened a door. The walking through took time.
4. Notice what you're hoping for. If you're hoping to be cured of grief, of addiction, of a diagnosis — that's a heavy expectation to carry into a ceremony. Most people who report lasting benefit went in curious, not desperate.

The research is genuinely promising. It's also early, and the most interesting findings come from settings where care, screening, and integration were taken seriously. If reading about studies like this has stirred something in you, the next step is probably less about booking the first retreat you find and more about understanding what a well-run one actually looks like.

For readers who want to take that next step thoughtfully, a curated range of psilocybin and plant-medicine retreats can be browsed on our marketplace here. Whatever you choose, choose slowly. The medicine isn't going anywhere, and the right setting is worth waiting for.